These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 19737999)
1. Controversies in the treatment of lymphoma with autologous transplantation. Moskowitz AJ; Moskowitz CH Oncologist; 2009 Sep; 14(9):921-9. PubMed ID: 19737999 [TBL] [Abstract][Full Text] [Related]
2. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults. Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N Cochrane Database Syst Rev; 2012 Jan; 1():CD007678. PubMed ID: 22258971 [TBL] [Abstract][Full Text] [Related]
3. Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study. Corazzelli G; Russo F; Capobianco G; Marcacci G; Della Cioppa P; Pinto A Ann Oncol; 2006 May; 17 Suppl 4():iv18-24. PubMed ID: 16702180 [TBL] [Abstract][Full Text] [Related]
4. Autologous stem cell transplantation for non-Hodgkin's lymphoma. Lin TS; Copelan EA Curr Hematol Rep; 2003 Jul; 2(4):310-5. PubMed ID: 12901328 [TBL] [Abstract][Full Text] [Related]
5. Role of hematopoietic stem cell transplantation for advanced-stage diffuse large cell B-cell lymphoma-B. Nademanee A; Forman SJ Semin Hematol; 2006 Oct; 43(4):240-50. PubMed ID: 17027658 [TBL] [Abstract][Full Text] [Related]
6. High-dose treatment with autologous haemopoietic progenitor cell support for large B-cell, follicular and mantle-cell lymphoma. Rohatiner AZ Best Pract Res Clin Haematol; 2002 Sep; 15(3):467-80. PubMed ID: 12468400 [TBL] [Abstract][Full Text] [Related]
7. Integrating monoclonal antibodies into the management of mantle cell lymphoma. Berinstein NL; Mangel J Semin Oncol; 2004 Feb; 31(1 Suppl 2):2-6. PubMed ID: 15042527 [TBL] [Abstract][Full Text] [Related]
8. Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study. Brugger W; Hirsch J; Grünebach F; Repp R; Brossart P; Vogel W; Kopp HG; Manz MG; Bitzer M; Schlimok G; Kaufmann M; Ganser A; Fehnle K; Gramatzki M; Kanz L Ann Oncol; 2004 Nov; 15(11):1691-8. PubMed ID: 15520073 [TBL] [Abstract][Full Text] [Related]
9. Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma. William BM; Allen MS; Loberiza FR; Bociek RG; Bierman PJ; Armitage JO; Vose JM Biol Blood Marrow Transplant; 2014 Apr; 20(4):536-42. PubMed ID: 24434781 [TBL] [Abstract][Full Text] [Related]
10. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma. Mangel J; Buckstein R; Imrie K; Spaner D; Crump M; Tompkins K; Reis M; Perez-Ordonez B; Deodhare S; Romans R; Pennell N; Robinson JB; Hewitt K; Richardson P; Lima A; Pavlin P; Berinstein NL Semin Oncol; 2002 Feb; 29(1 Suppl 2):56-69. PubMed ID: 11842390 [TBL] [Abstract][Full Text] [Related]
12. Durable event-free survival following autologous stem cell transplant for relapsed or refractory follicular lymphoma: positive impact of recent rituximab exposure and low-risk Follicular Lymphoma International Prognostic Index score. Peters AC; Duan Q; Russell JA; Duggan P; Owen C; Stewart DA Leuk Lymphoma; 2011 Nov; 52(11):2124-9. PubMed ID: 21740097 [TBL] [Abstract][Full Text] [Related]
13. Chemoresistance can be overcome with high-dose chemotherapy and autologous stem-cell transplantation for relapsed and refractory Hodgkin lymphoma. Gerrie AS; Power MM; Shepherd JD; Savage KJ; Sehn LH; Connors JM Ann Oncol; 2014 Nov; 25(11):2218-2223. PubMed ID: 25149708 [TBL] [Abstract][Full Text] [Related]
14. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Plosker GL; Figgitt DP Drugs; 2003; 63(8):803-43. PubMed ID: 12662126 [TBL] [Abstract][Full Text] [Related]
15. Refining the Mantle Cell Lymphoma Paradigm: Impact of Novel Therapies on Current Practice. Avivi I; Goy A Clin Cancer Res; 2015 Sep; 21(17):3853-61. PubMed ID: 26059189 [TBL] [Abstract][Full Text] [Related]
16. [Autologous hematopoietic stem cell transplantation for aggressive B-cell non-Hodgkin's lymphoma]. Hirose A; Yamane T; Nakajima Y; Manabe M; Kanashima H; Hagihara K; Sakamoto E; Nakamae M; Terada Y; Kosaka S; Aoyama Y; Sakamoto C; Kumura T; Koh KR; Hirai M; Ohta K; Nakao Y; Mugitani A; Teshima H; Hino M Gan To Kagaku Ryoho; 2005 Dec; 32(13):2059-64. PubMed ID: 16352929 [TBL] [Abstract][Full Text] [Related]
17. High-dose chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: complete response at transplant predicts survival. Kim MK; Kim S; Lee SS; Sym SJ; Lee DH; Jang S; Park CJ; Chi HS; Huh J; Suh C Ann Hematol; 2007 Jun; 86(6):435-42. PubMed ID: 17256144 [TBL] [Abstract][Full Text] [Related]
18. [Follicular lymphoma: first - line selection criteria of treatment]. Nesterova ES; Kravchenko SK; Kovrigina AM; Gemdzhian EG; Plastinina LV; Babaeva FE; Obukhova TN; Magomedova AU; Gaponova TV; Kremenetskaya AM; Vorobyev AI Ter Arkh; 2019 Aug; 91(8):75-83. PubMed ID: 32598757 [TBL] [Abstract][Full Text] [Related]
19. Peripheral T-cell lymphoma: the role of hematopoietic stem cell transplantation. Gkotzamanidou M; Papadimitriou CA Crit Rev Oncol Hematol; 2014 Feb; 89(2):248-61. PubMed ID: 24075060 [TBL] [Abstract][Full Text] [Related]
20. Clinical characteristics and outcomes of relapsed follicular lymphoma after autologous stem cell transplantation in the rituximab era. Sesques P; Bourcier J; Golfier C; Lebras L; Nicolas-Virelizier E; Hacini M; Perrin MC; Voillat L; Bachy E; Traverse-Glehen A; Moreau A; Martin L; Ramla S; Casasnovas O; Le Gouill S; Salles G; Ghesquières H Hematol Oncol; 2020 Apr; 38(2):137-145. PubMed ID: 31953963 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]